We herein demonstrate the therapeutic effects of CBIT2 in ALS, with evidence of disease reversal and restoration of motor neuron function, as validated by objective neuromuscular assessments, normalization of molecular biomarker, reconstitution of tongue structure, and upregulation of HSP expression. This evidence concerns the gene HSP90B2P and amyotrophic lateral sclerosis.